• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Incidence and Factors Associated With Spontaneous Regression in Head and Neck Lymphatic Malformations.头颈部淋巴管畸形自发消退的发生率及相关因素
JAMA Otolaryngol Head Neck Surg. 2025 May 1;151(5):503-512. doi: 10.1001/jamaoto.2025.0104.
2
Delaying Invasive Treatment in Unilateral Head and Neck Lymphatic Malformation Improves Outcomes.延迟单侧头颈部淋巴管畸形的侵入性治疗可改善预后。
Laryngoscope. 2023 Apr;133(4):956-962. doi: 10.1002/lary.30237. Epub 2022 Jun 3.
3
Treatments and Outcomes of Pediatric Head and Neck Lymphatic Malformations: A 20-Year Single Institution Experience.小儿头颈部淋巴管畸形的治疗与预后:一项20年单机构经验
Otolaryngol Head Neck Surg. 2025 Mar;172(3):1026-1035. doi: 10.1002/ohn.1077. Epub 2024 Dec 15.
4
Active Observation as an Alternative to Invasive Treatments for Pediatric Head and Neck Lymphatic Malformations.主动观察作为小儿头颈部淋巴畸形的侵袭性治疗的替代方法。
Laryngoscope. 2021 Jun;131(6):1392-1397. doi: 10.1002/lary.29180. Epub 2020 Oct 27.
5
Surgical resection of macrocystic lymphatic malformations of the head and neck: Short and long-term outcomes.头颈部大囊型淋巴管畸形的手术切除:短期和长期结果
Int J Pediatr Otorhinolaryngol. 2020 Jul;134:110013. doi: 10.1016/j.ijporl.2020.110013. Epub 2020 Mar 20.
6
Association between malformation type, location and functional deficits in lymphatic malformations of the head and neck in children.头颈部淋巴管畸形患儿畸形类型、部位与功能障碍的相关性研究。
Eur Arch Otorhinolaryngol. 2023 May;280(5):2535-2540. doi: 10.1007/s00405-023-07844-x. Epub 2023 Jan 25.
7
Healthcare utilization in patients with head and neck lymphatic malformations with the introduction of sirolimus.西罗莫司引入对头颈部淋巴管畸形患者医疗利用情况的影响
Am J Otolaryngol. 2024 Nov-Dec;45(6):104422. doi: 10.1016/j.amjoto.2024.104422. Epub 2024 Jul 24.
8
Management of the head and neck lymphatic malformations in children: A 7-year experience of 91 surgical cases.儿童头颈部淋巴管畸形的治疗:91 例手术病例 7 年经验。
Am J Otolaryngol. 2023 Jul-Aug;44(4):103897. doi: 10.1016/j.amjoto.2023.103897. Epub 2023 Apr 12.
9
Percutaneous sclerotherapy with ethanolamine oleate for lymphatic malformations of the head and neck.经皮注射油酸乙醇胺硬化治疗头颈部淋巴管畸形
J Neurointerv Surg. 2014 Nov;6(9):691-4. doi: 10.1136/neurintsurg-2013-010925. Epub 2013 Oct 23.
10
Clinical analysis of surgical treatment for head and neck lymphatic malformations in children: a series of 128 cases.儿童头颈部淋巴管畸形手术治疗的临床分析:128例病例系列
Acta Otolaryngol. 2019 Aug;139(8):713-719. doi: 10.1080/00016489.2019.1616818. Epub 2019 Jun 6.

本文引用的文献

1
Primary targeted medical therapy for management of bilateral head and neck lymphatic malformations in infants.婴儿双侧头颈部淋巴管瘤的主要靶向药物治疗。
Int J Pediatr Otorhinolaryngol. 2023 Jan;164:111371. doi: 10.1016/j.ijporl.2022.111371. Epub 2022 Nov 15.
2
Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.阿培利司治疗 PI3KCA 相关的头颈部淋巴管畸形和过度生长。
Genet Med. 2022 Nov;24(11):2318-2328. doi: 10.1016/j.gim.2022.07.026. Epub 2022 Sep 6.
3
Delaying Invasive Treatment in Unilateral Head and Neck Lymphatic Malformation Improves Outcomes.延迟单侧头颈部淋巴管畸形的侵入性治疗可改善预后。
Laryngoscope. 2023 Apr;133(4):956-962. doi: 10.1002/lary.30237. Epub 2022 Jun 3.
4
Sclerosing agents in the management of lymphatic malformations in children: A systematic review.硬化剂在儿童淋巴管畸形治疗中的应用:系统评价。
J Pediatr Surg. 2022 May;57(5):888-896. doi: 10.1016/j.jpedsurg.2021.12.056. Epub 2022 Jan 14.
5
Expectant management of pediatric lymphatic malformations: A 30-year chart review.小儿淋巴管瘤的期待治疗:30 年图表回顾。
J Pediatr Surg. 2022 May;57(5):883-887. doi: 10.1016/j.jpedsurg.2021.12.053. Epub 2022 Jan 14.
6
Acetylsalicylic acid suppression of the PI3K pathway as a novel medical therapy for head and neck lymphatic malformations.阿司匹林抑制 PI3K 通路作为头颈部淋巴管畸形的一种新的医学治疗方法。
Int J Pediatr Otorhinolaryngol. 2021 Dec;151:110869. doi: 10.1016/j.ijporl.2021.110869. Epub 2021 Aug 5.
7
Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.两例 PI3KCA 相关过度生长综合征患儿应用 AKT1 抑制剂 miransertib 的临床经验。
Orphanet J Rare Dis. 2021 Feb 27;16(1):109. doi: 10.1186/s13023-021-01745-0.
8
Active Observation as an Alternative to Invasive Treatments for Pediatric Head and Neck Lymphatic Malformations.主动观察作为小儿头颈部淋巴畸形的侵袭性治疗的替代方法。
Laryngoscope. 2021 Jun;131(6):1392-1397. doi: 10.1002/lary.29180. Epub 2020 Oct 27.
9
Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations.无细胞游离 DNA 作为血管畸形分子诊断的诊断分析物。
Genet Med. 2021 Jan;23(1):123-130. doi: 10.1038/s41436-020-00943-8. Epub 2020 Sep 4.
10
Surgical resection of macrocystic lymphatic malformations of the head and neck: Short and long-term outcomes.头颈部大囊型淋巴管畸形的手术切除:短期和长期结果
Int J Pediatr Otorhinolaryngol. 2020 Jul;134:110013. doi: 10.1016/j.ijporl.2020.110013. Epub 2020 Mar 20.

头颈部淋巴管畸形自发消退的发生率及相关因素

Incidence and Factors Associated With Spontaneous Regression in Head and Neck Lymphatic Malformations.

作者信息

Bonilla-Velez Juliana, Heike Carrie L, Kessler Larry G, Wang Xing, Wenger Tara L, Ramsey Bonnie W, Perkins Jonathan A

机构信息

Division of Pediatric Otolaryngology-Head and Neck Surgery, Seattle Children's Hospital, Seattle, Washington.

Department of Otolaryngology-Head and Neck Surgery, University of Washington School of Medicine, Seattle.

出版信息

JAMA Otolaryngol Head Neck Surg. 2025 May 1;151(5):503-512. doi: 10.1001/jamaoto.2025.0104.

DOI:10.1001/jamaoto.2025.0104
PMID:40146172
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11950974/
Abstract

IMPORTANCE

Head and neck lymphatic malformations (HNLMs) demonstrate considerable variability in their natural history. While some malformations cause chronic severe functional impairment, others are asymptomatic and spontaneously regress. Understanding the frequency and features associated with regression will aid clinicians and families in making informed treatment choices and avoid unnecessary risks of intervention for a subset of patients.

OBJECTIVE

To assess the incidence, timing, and factors associated with spontaneous regression of HNLMs.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study across a single regional pediatric tertiary care academic center included patients aged 0 to 21 years with HNLM who were evaluated in the vascular anomalies clinic and prospectively enrolled in an institutional quality improvement database between 2003 and 2022. Observation was offered to patients without symptoms or functional compromise. Treatment decisions were made during routine clinical care.

EXPOSURES

Age of HNLM onset and HNLM location, distribution, cystic structure, grade, and de Serres staging.

MAIN OUTCOME AND MEASURES

The incidence of complete spontaneous regression was estimated. The strength of the association between exposures and regression was assessed using risk ratios, Cliff Δ, and Cramer V. A Kaplan-Meier curve was used to estimate the probability of spontaneous regression over time. The association of the exposures on the likelihood of spontaneous regression were assessed using 2-sided log-rank tests and Cox proportional hazards models.

RESULTS

Of 298 patients with HNLMs, 173 (58.1%) were male, and most HNLMs were diagnosed prenatally or at birth (137 patients [46.0%]). Among HNLMs, 189 (63.4%) had a focal distribution, 228 (76.5%) were de Serres stage I or II, and 128 (43.0%) were macrocystic. Complete spontaneous regression occurred in 27 patients (9.1%) at a median (IQR) time of 12.0 (6.7-27.4) months from onset. Factors associated with a large difference in the rate of complete spontaneous regression included macrocystic structure, neck location, focal distribution, and grade 1 or de Serres I stage. HNLMs of the upper face or midface, with mixed or microcystic composition, or with extensive unilateral or bilateral involvement did not regress.

CONCLUSIONS AND RELEVANCE

In this cohort study, HNLMs that were macrocystic, of limited extent, and/or in the neck were more likely to completely spontaneously regress. A 1-year observation period for asymptomatic HNLM, particularly when favorable features are present, should be considered, as nonintervention may be curative. Future studies will examine interaction among these factors. This work contributes to a deeper understanding of HNLM natural history that can directly inform clinical decision-making, decrease treatment risk, and optimize patient outcomes.

摘要

重要性

头颈部淋巴管畸形(HNLMs)在其自然病程中表现出相当大的变异性。虽然一些畸形会导致慢性严重功能障碍,但其他畸形则无症状且会自发消退。了解与消退相关的频率和特征将有助于临床医生和家庭做出明智的治疗选择,并避免对一部分患者进行不必要的干预风险。

目的

评估HNLMs自发消退的发生率、时间及相关因素。

设计、设置和参与者:这项针对单个地区儿科三级医疗学术中心的回顾性队列研究纳入了0至21岁患有HNLMs的患者,这些患者在血管异常诊所接受评估,并于2003年至2022年期间前瞻性纳入机构质量改进数据库。对无症状或无功能损害的患者进行观察。治疗决策在常规临床护理期间做出。

暴露因素

HNLMs的发病年龄、位置、分布、囊性结构、分级和de Serres分期。

主要结局和测量指标

估计完全自发消退的发生率。使用风险比、Cliff Δ和Cramer V评估暴露因素与消退之间的关联强度。采用Kaplan-Meier曲线估计随时间自发消退的概率。使用双侧对数秩检验和Cox比例风险模型评估暴露因素对自发消退可能性的关联。

结果

在298例HNLMs患者中,173例(58.¹%)为男性,大多数HNLMs在产前或出生时被诊断(137例患者[46.0%])。在HNLMs中,189例(63.4%)呈局灶性分布,228例(76.5%)为de Serres I期或II期,128例(43.0%)为大囊型。27例患者(9.1%)出现完全自发消退,从发病开始的中位(IQR)时间为12.0(6.7 - 27.4)个月。与完全自发消退率差异较大相关的因素包括大囊型结构、颈部位置、局灶性分布以及1级或de Serres I期。上脸或中脸的HNLMs,具有混合或微囊型成分,或有广泛的单侧或双侧受累则不会消退。

结论及相关性

在这项队列研究中,大囊型、范围有限和/或位于颈部的HNLMs更有可能完全自发消退。对于无症状的HNLMs应考虑进行为期1年的观察期,特别是当存在有利特征时,因为不干预可能治愈。未来的研究将考察这些因素之间的相互作用。这项工作有助于更深入地了解HNLMs的自然病程,可直接为临床决策提供信息,降低治疗风险,并优化患者结局。